

Angiocrine Bioscience Licenses New Stem Cell Technology

Advances in Cell Based Assays, 11th & 12th November 2014, London UK

LONDON, LONDON, UNITED KINGDOM, August 27, 2014 /EINPresswire.com/ -- Angiocrine Bioscience announced in a press release last week that it has licensed the rights to a new technology developed by a team of researchers at the Ansary Stem Cell Institute at Weill Cornell Medical College. This scientific advance, reported in the July 2 issue of Nature, could potentially lead to therapies for patients with blood disorders from their own cells.

“This technology nicely complements our efforts in applying our VeraVec™ platform to the expansion of umbilical cord blood stem cells, another approach toward making stem cell transplant safer and more broadly available to patients in need,” said Geoff Davis, Angiocrine’s CEO.* Source <http://www.digitaljournal.com/pr/2136364>



Hear more from Angiocrine Bioscience at [Advances in Cell Based Assays](#) this autumn as Director of Research, Dr Daniel Nolan, provides further insights into the VeraVec™ platform.



Angiocrine Bioscience is excited to attend the 7th Annual CBA conference as we expand our collaborations into Europe”
Dr Daniel Nolan, Angiocrine Bioscience

The [talk](#) will discuss recent works demonstrating how the chemoresistant niche within cancer involves the vasculature, a look into how the vascular stem cell niche is capable of expanding stem cells in vitro while maintaining potency and engraftability, plus VeraVec™ amenability to 3D and co-culture assays for screening purposes.

Other Speakers Include:

Steve Ludbrook, Group Leader, Biological Sciences UK, RD Platform Technology & Science, GSK

Beverley Isherwood, Team Leader High Content Biology, Innovative Medicines, AstraZeneca

R&D

Dr Lesley Jenkinson, Scientist 1, MedImmune

Dr Farnaz Fallah-Arani, Group Leader, Pharmacology, UCB

Neil Carragher, PhD, Principal Investigator Drug Discovery, Edinburgh Cancer Research UK Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh

Niclas Nilsson, Head of Section, Lead Discovery, LEO Pharma

Dr Christa Burger, Principal Scientist, Cellular Pharmacology, Merck Serono

Dr Marianne Uteng, PhD, Head of Cellular Models & HCB Laboratory, Discovery and Investigative Safety (DIS), Novartis

For further details and to secure a place at Advances in Cell Based Assays, visit

www.cellbasedassay.co.uk

7th annual conference:

Advances in Cell Based Assays

11th & 12th November 2014

Marriott Regents Park Hotel, London UK

www.cellbasedassay.co.uk

---end---

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. We hold events in over 30 major cities throughout the world including London, Paris and Singapore and to date have welcomed over 200,000 participants from 80 countries. More information can be found at <http://www.smi-online.co.uk>

Teri Arri

SMi Group Ltd

+44 (0)20 7827 6162

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/220616193>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

